{
  "ticker": "LLY",
  "timestamp": "2025-12-01T10:14:47.281470",
  "analysis_date": "2024-07-01",
  "historical_mode": true,
  "portfolio_value": 100000.0,
  "verdict": "REJECT",
  "final_position_pct": 0,
  "final_position_dollars": 0.0,
  "confidence": "LOW",
  "reasoning": "While Eli Lilly and Company (LLY) presents strong financial metrics and growth potential, the current market conditions indicate overbought levels, increasing the risk of a pullback. Additionally, the lack of a comprehensive analysis due to LLM unavailability introduces uncertainty that cannot be overlooked. Therefore, exercising prudence and rejecting this trade aligns with our risk management strategy.",
  "key_factors": [
    "Overbought market conditions",
    "Incomplete analysis due to LLM failure",
    "Risk management considerations"
  ],
  "conditions": [
    "High volatility potential",
    "Uncertain earnings outlook"
  ],
  "stop_loss_pct": 15,
  "profit_targets": [
    12.5,
    18.8,
    25
  ],
  "guardrail_corrections": [],
  "is_llm_decision": true,
  "risk_controls": {
    "stop_loss": {
      "percentage": 15,
      "dollar_amount": 0.0
    },
    "take_profit": {
      "targets": [
        12.5,
        18.8,
        25
      ],
      "scale_out": [
        0.33,
        0.33,
        0.34
      ]
    },
    "time_limit": {
      "max_holding_period": "90 days",
      "review_frequency": "weekly"
    }
  },
  "risk_consensus": {
    "stances": {
      "aggressive": "HOLD",
      "neutral": "SMALL BUY",
      "conservative": "HOLD"
    },
    "position_sizes": {
      "aggressive": 5.0,
      "neutral": 12.0,
      "conservative": 0
    },
    "agreements": [],
    "conflicts": [
      "Mixed views: 1 buy, 0 avoid"
    ],
    "avg_position_size": 0.056666666666666664,
    "red_flags": [
      {
        "flag": "Analysis failed",
        "severity": "HIGH",
        "source": "System"
      }
    ]
  },
  "position_sizing": {
    "range_min_pct": 0.0,
    "range_max_pct": 0.0,
    "final_pct": 0,
    "final_dollars": 0.0
  },
  "agent_votes": {
    "bullish": 2,
    "bearish": 0,
    "neutral": 2,
    "consensus": "LEAN_BULLISH"
  },
  "research_recommendation": "BUY",
  "report": "\n======================================================================\nRISK MANAGER FINAL DECISION: LLY\n======================================================================\n**Analysis Date:** 2024-07-01 (HISTORICAL)\n**Portfolio:** $100,000\n\n## VERDICT: REJECT\n**Position:** No position taken\n**Confidence:** LOW\n\n## REASONING\nWhile Eli Lilly and Company (LLY) presents strong financial metrics and growth potential, the current market conditions indicate overbought levels, increasing the risk of a pullback. Additionally, the lack of a comprehensive analysis due to LLM unavailability introduces uncertainty that cannot be overlooked. Therefore, exercising prudence and rejecting this trade aligns with our risk management strategy.\n\n## KEY FACTORS\n\u2022 Overbought market conditions\n\u2022 Incomplete analysis due to LLM failure\n\u2022 Risk management considerations\n\n## EVALUATOR SUMMARY\n- Aggressive: HOLD @ 5.0%\n- Neutral: SMALL BUY @ 12%\n- Conservative: HOLD @ 0%\n\n## AGENT CONSENSUS\n- Bullish Votes: 2/4\n- Bearish Votes: 0/4\n- Neutral Votes: 2/4\n- Overall: Lean Bullish\n\n## POSITION SIZING\n- Range: 0.0% - 0.0%\n- Final: 0.00% ($0.00)\n\n## RISK CONTROLS\n- Stop Loss: -15%\n- Profit Targets: +12.5%, +18.8%, +25%\n\n## CONDITIONS\n\u2022 High volatility potential\n\u2022 Uncertain earnings outlook\n\n======================================================================\n"
}